期刊文献+

阴茎硬结症非手术治疗现状与展望

Current status and prospects of non-surgical management of Peyronie's disease
下载PDF
导出
摘要 阴茎硬结症(PD)是遗传易感者阴茎反复的微血管或白膜损伤后愈合紊•乱导致结缔组织形成纤维化斑块的疾病,表现为阴茎畸形、勃起功能障碍和阴茎疼痛。PD发病机制尚不完全清楚,其治疗仍然是一个难题。非手术治疗主要用于PD早期患者,以减轻疼痛,防止疾病进展,包括口服药物治疗、局部治疗、机械治疗等;近年来出现一些新的治疗方法,然而由于缺乏大样本的临床研究,这些治疗方法的价值很难评估。为了更好地指导阴茎硬结症早期治疗,现对阴茎硬结症的非手术治疗现状做一综述。 Peyronie's disease(PD)is considered to be a disease in which the connective tissue forms fibrotic plaques after repeated capillary or albuginea injuries in the penis of genetically susceptible individuals.Manifested as penile erectile deformity,erectile dysfunction and penile pain.Because the pathogenesis is not fully understood,the treatment of PD is still a difficult problem.Non-surgical treatments are mainly used for patients in the early stage of the disease to relieve pain and prevent disease progression,including oral drug treatment,topical treatment,mechanical treatment,etc.In recent years,some new treatment methods have emerged.However,there are little large sample clinical studies accurately evaluating the safety and effectiveness of these treatments.In this review,we provide a overview of the current non-surgical treatments of Peyronie's disease.
作者 王茹艺(综述) 柳良仁(审校) 董强(审校) WANG Ruyi;LIU Liangren;DONG Qiang(Department of Urology,West China Hospital,Sichuan Universtiy,Chengdu 610041,China;Department of Urology,The Affiliated Hospital of Chengdu Universtiy,Chengdu 610000,China)
出处 《西部医学》 2022年第8期1244-1248,F0003,共6页 Medical Journal of West China
基金 四川省科技厅科技计划项目(2020YJ0054)。
关键词 阴茎硬结症 非手术治疗 联合治疗 Peyronie's disease Non-surgical treatments Combination therapy
  • 相关文献

参考文献9

二级参考文献63

  • 1Muller A, Mulhall JP. Peyronie's disease intervention trials: Methodological challenges and issues. J Sex Med, 2009, 6 (3) : 848-861.
  • 2Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie's disease: Evidence-based 2010 guidelines . J Sex Med, 2010, 7(7) : 2359-2374.
  • 3Tal R, Hall MS, Alex B, et al. Peyronie's disease in teenagers. J Sex Med, 2012, 9(1 ): 302-308.
  • 4Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease : Therapeutic" rationale" and related emerging treatment strategies. Inilamm Allergy Drug Targets, 2012, 11(1) : 48-57.
  • 5Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1 beta and transfor- ming growth factor-beta in Peyronie's plaque fibroblasts. J Urol, 2008, 179(6): 2447-2455.
  • 6Jang JH, Ryu JK, Suh JK. Activin receptor-like kinase 5 inhibi- tor attenuates fibrosis in fibroblasts derived from Peyronie "s plaque. Korean J Urol, 2012, 53(1) : 44-49.
  • 7Nam HJ, Park HJ, Park NC. Does testosterone deficiency exaggerate the clinical symptoms of Peyronie's disease7 Int J Urol, 2011, 18(11) : 796-800.
  • 8Dolmans GH, Werker PM, de Jong I J, et al. WNT2 locus is involved in genetic susceptibility of Peymnie- disease. J Sex Med, 2012, 9(5) : 1430-1434.
  • 9Acikgoz A, Gokce E, Asci R, et al. Relationship between penile fracture and Peyronieg disease: A prospective study. Int J Impot Res, 2011,23(4) : 165-172.
  • 10Chung E, Yah H, De Young L, et al. Penile Doppler sonographic and clinical characteristics in Peyronieg disease and/or erectile dysfunction: An analysis of 1 500 men with male sexual dysfunction. BJU Int, 2012, 110(8) : 1201-1205.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部